BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31588879)

  • 1. Impact of
    Huang L; Wang J; Yang J; Zhang H; Ni Y; Zhu Z; Wang H; Gao P; Wu Y; Mao J; Fang L
    Pharmacogenomics; 2019 Oct; 20(15):1071-1083. PubMed ID: 31588879
    [No Abstract]   [Full Text] [Related]  

  • 2. Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.
    Wang J; Huang L; Gao P; Hu Y; Ni Y; Zhu Z; Zhang L; Yang J; Zhang H; Fang L
    Eur J Clin Pharmacol; 2021 Jan; 77(1):71-77. PubMed ID: 32803289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome.
    Li M; Xu M; Liu W; Gao X
    BMC Pharmacol Toxicol; 2018 Apr; 19(1):14. PubMed ID: 29615122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.
    Huang L; Liu Y; Jiao Z; Wang J; Fang L; Mao J
    Eur J Pharm Sci; 2020 Feb; 143():105199. PubMed ID: 31862313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
    Vanhove T; Annaert P; Lambrechts D; Kuypers DRJ
    Pharmacogenomics J; 2017 Dec; 17(6):556-562. PubMed ID: 27378609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
    Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
    Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients.
    Li JL; Liu S; Fu Q; Zhang Y; Wang XD; Liu XM; Liu LS; Wang CX; Huang M
    Pharmacogenomics; 2015; 16(12):1355-65. PubMed ID: 26228923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
    Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
    Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
    Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
    Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
    Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.
    Sy SK; Heuberger J; Shilbayeh S; Conrado DJ; Derendorf H
    AAPS J; 2013 Oct; 15(4):1189-99. PubMed ID: 23990505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria.
    Liu H; Xu Q; Huang W; Zhao Q; Jiang Z; Kuang X; Li Z; Sun H; Qiu X
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1533-1540. PubMed ID: 31401678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.
    Wang XF; Yan L; Cao HM; Wei LM; Yang WH; Zhang SJ; Zhang LR
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):737-45. PubMed ID: 26104034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients.
    Zhang Y; Li JL; Fu Q; Wang XD; Liu LS; Wang CX; Xie W; Chen ZJ; Shu WY; Huang M
    Acta Pharmacol Sin; 2013 Apr; 34(4):555-60. PubMed ID: 23503472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus treatment in childhood refractory nephrotic syndrome: A retrospective study on efficacy, therapeutic drug monitoring, and contributing factors to variable blood tacrolimus levels.
    Guo HL; Xu J; Sun JY; Li L; Guo HL; Jing X; Xu ZY; Hu YH; Xu ZJ; Sun F; Ding XS; Chen F; Zhao F
    Int Immunopharmacol; 2020 Apr; 81():106290. PubMed ID: 32058933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.